[Hepatotoxicity of valproic acid treatment].
Hepatotoxicity of valproic acid (VPA) is reported in a psychomotor retarded boy. A four-month antiepileptic therapy was followed by a combined VPA/phenytoin treatment where-upon, two months later, the patient died in a hepatic coma. In the final state the metabolic pattern of VPA was still found within the normal range with the exception of the two abnormal metabolites 4-en-VPA) (2-propyl-4-pentenoic acid) and 4.4'-dien-VPA (2-(2-propenyl-4-pentenoic acid) detected only in low concentration. The amino acid pattern in plasma was characterized by a decrease or branched chain amino acids by 50% in contrast to the increase of the aromatic amino acids. Methionine, however, was in the normal range. Due to lack of a biochemical parameter indicating a possibly irreversible development of VPA induced hepatotoxicity stopping of VPA therapy should be obligatory if abnormal unsaturated VPA metabolites are detected or if dien-VPA/3, a normal metabolic compound, is increased above the normal range. L-carnitine treatment is recommended as a prophylactic therapy.
D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004830:Epilepsy, Tonic-Clonic / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008297:Male; D011596:Psychomotor Disorders / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors; D014635:Valproic Acid / Q000378:metabolism / Q000506:poisoning*
D014635:Valproic Acid
Hepatotoxizität unter Valproinsäurebehandlung.